Small molecule fibrosis inhibitors: at the heart of our R&D strategy
Galecto is committed to developing novel therapeutics for end-stage fibrotic conditions and cancers with a high unmet medical need.
Fibrosis is a severe scarring process that occurs in many chronic diseases of the lungs, liver, kidneys, heart, joints and eye. It can severely disrupt organ functions, leading to irreversible failure, the need for transplant, and can also be fatal in some cases.
Galecto’s small molecule pipeline targets two key, potentially synergistic proteins involved in the fibrotic process, galectin-3 and LOXL2.
Galectin-3 (Gal-3) has a well described role in inflammation, including the recruitment and activation of a number of immune cells, such as macrophages and T-cells. Gal-3 can also drive the release of cytokines and other immune signaling molecules to cause organ damage and dysfunction.
LOXL2 is an enzyme that catabolizes the formation of lysine cross-linking in fibrillar collagens, a common feature among multiple fibrotic indications.